Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: Involvement of dopamine in the medial prefrontal cortex

Behavioural Pharmacology

Volumn 15, Issue 5-6, 2004, Pages 433-442

  Ventura, R ^a,b   Pascucci, T ^a,b   Catania, M V ^c,d   Musumeci, S A ^c   Puglisi Allegra, S ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Istituto di Ricovero e Cura A Carattere Scientifico   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

^d INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

Author keywords

Caudatus putamen; D amphetamine; Dopamine; Fmr1 knockout mice; Fragile X syndrome; Microdialysis; Object recognition test; Prefrontal cortex

Indexed keywords

AMPHETAMINE; DOPAMINE; PSYCHOSTIMULANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; FRAGILE X SYNDROME; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; STRIATE CORTEX; TASK PERFORMANCE; WILD TYPE;

EID: 4544383988     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200409000-00018     Document Type: Article

References (53)

1. Arnsten AFT (1997). Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151-162.
2. Chen L, Toth M (2001). Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103:1043-1050.
3. Davids E, Zhang K, Tarazi FI, Baldessarini RJ (2003). Animal models of attention-deficit hyperactivity disorder. Brain Res Rev 42:1-21.
4. Dobkin C, Rabe A, Dumas R, El Idrissi A, Haubenstock H, Brown WT (2000). Fmr1 knockout mice have a distinctive strain-specific learning impairment. Neuroscience 94:185-192.
5. Dutch-Belgian Fragile X Consortium (1994). Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23-33.
6. Ennaucer A, Delacour J (1988). A new one-trial test for neurobiological studies of memory in rats. I. Behavioural data. Behav Brain Res 31:47-59.
7. Evangelista AM, Izquierdo I (1971). The effect of pre- and post-trial amphetamine injections on avoidance responses of rats. Psychopharmacology (Berl) 20:42-47.
8. Fisch GS, Hao HK, Bakker C, Oostra BA (1999). Learning and memory in the FMR1 knockout mouse. Am J Med Genet 84:277-282.
9. Franklin KBJ, Paxinos G (1998). The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press.
10. Freund LS, Reiss AL (1991). Cognitive profiles associated with the fra (X) syndrome in males and females. Am J Med Genet 38:542-547.
11. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999). Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397-401.
12. Goldman-Rakic PS (1996). Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 93:13473-13480.
13. Gruss M, Braun K (2004). Age- and region-specific imbalances of basal amino acids and monoamine metabolism in limbic regions of female Fmr1 knock-out mice. Neurochem Int 45:81-88.
14. Hagerman RJ (1996). Physical and behavioral phenotype. In: Hagerman RJ, Silverman AC (editors): Fragile X Syndrome: Diagnosis, Treatment, and Research. Baltimore: Johns Hopkins University Press; pp. 3-87.
15. Himelstein J, Newcorn JH, Halperin JM (2000). The neurobiology of attention-deficit hyperactivity disorder. Front Biosci 5:D461-D478.
16. Hinton VJ, Brown WT, Wisniewski K, Rudelli RD (1991). Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet 41:289-294.
17. Hjalgrim H, Jacobsen T, Norgaard K, Lou HC, Brondum-Nielsen K, Jonassen O (1999). Frontal-subcortical hypofunction in the Fragile X Syndrome. Am J Med Gen 83:140-141.
18. Irwin SA, Galvez R, Greenough WT (2000). Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:1038-1044.
19. Ivanco TL, Greenough WT (2002). Altered mossy fiber distributions in adult Fmr1 (FVB) knockout mice. Hippocampus 12:47-54.
20. Johnson FN, Waite K (1971). Apparent delayed enhancement of memory following post-trial methylamphetamine hydrochloride. Experientia 27: 1316-1317.
21. Kemper MB, Hagerman RJ, Altshul SD (1988). Cognitive profiles of boys with the fragile X syndrome. Am J Med Genet 30:190-200.
22. Kempton S, Vance A, Maruff P, Luk E, Costin J, Pantelis C (1999). Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med 29:527-538.
23. Kooy RF, D'Hooge R, Reyniers E, Bakker CE, Nagels G, De Boulle K, et al. (1996). Transgenic mouse model for the fragile X syndrome. Am J Med Genet 64:241-245.
24. Levy R, Friedman HR, Davachi L, Goldman-Rakic PS (1997). Differential activation of the caudate nucleus in primates performing spatial and nonspatial working memory tasks. J Neurosci 17:3870-3882.
25. Madras BK, Miller GM, Fischman AJ (2002). The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res 130:57-63.
26. McGaugh JL (1973). Drug facilitation of learning and memory. Annu Rev Pharmacol 13:229-241.
27. Metha M, Robbins TW, Sahakian B (2001). Comparative psychopharmacology of methylphenidate and related drugs in human volunteers, patients w/ADHD and experimental animals. In: Solanto MV, Arnsten AFT, Castellanos FX (editors): Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York: Oxford University Press; pp. 303-331.
28. Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE (2002). Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12:39-46.
29. Nielsen DM, Derber WJ, McClellan DA, Crnic LS (2002). Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 927:8-17.
30. Packard MG, White NM (1989). Memory facilitation produced by dopamine agonists: role of receptor subtype and mnemonic requirements. Pharmacol Biochem Behav 33:511-518.
31. Partiot A, Verin M, Pillon B, Teixeira-Ferreira C, Agid Y, Dubois B (1996). Delayed response tasks in basal ganglia lesions in man: further evidence for a striatofrontal cooperation in behavioural adaptation. Neuropsychologia 34: 709-721.
32. Pieretti M, Zhang F, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817-822.
33. Pontieri FE, Tanda G, Di Chiara G (1995). Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the 'shell' as compared with the 'core' of the rat nucleus accumbens. Prac Natl Acad Sci USA 92:12304-12308.
34. Quin M, Kang J, Smith CB (2002). Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:15758-15763.
35. Rapaport JL, Buchsabaum MS, Weingartner H, Zahn TP, Ludlov C, Mikkelsen EJ (1980). Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943.
36. Reiss AL, Abrams MT, Greenlaw R, Freund L, Denckla MB (1995). Neurodevelopment effects of the FMR-1 full mutation in human. Nat Med 1: 159-167.
37. Rudelli RD, Brown WT, Wisniewski K, Jenkins EC, Laure-Kamionowska M, Connell F, Wisniewski HM (1985). Adult fragile X syndrome: clinico- neuropathologic findings. Acta Neuropathol (Berl) 67:289-295.
38. Russel VA (2002). Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res 130: 191-196.
39. Solanto MV (1998). Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94:127-152.
40. Solanto MV (2002). Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130:65-71.
41. Spink AJ, Tegelenbosch RA, Buma MO, Noldus LP (2001). The EthoVision video tracking system - a tool for behavioral phenotyping of transgenic mice. Physiol Behav 73:731-744.
42. Strupp BJ, Bunsey M, Levitsky D, Kesler M (1991). Time-dependent effects of post-trial amphetamine treatment in rats: evidence for enhanced storage of representational memory. Behav Neural Biol 56:62-76.
43. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST (1992). DNA methylation represses FMR1 transcription in fragile X syndrome. Hum Mol Genet 1:397-400.
44. Swanson JM, Kinsbourne MK (1976). Stimulant-related state-dependent learning in hyperactive children. Science 192:1354-1357.
45. Tannock R, Ickowiz A, Schachar R (1995). Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 34:886-896.
46. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF (2000). Functional deficit in basal ganglia of children with attention-deficit hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med 6:470-473.
47. Turner G, Webb T, Wake S, Robinson H (1996). Prevalence of fragile X syndrome. Am J Med Genet 64:196-197.
48. Van Dam D, D'Hooge R, Hauben E, Reyniers E, Gantois I, Bakker CE, et al. (2000). Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav Brain Res 117: 127-136.
49. Ventura R, Alcaro A, Mandolesi L, Puglisi-Allegra S (2004). In vivo evidence that genetic background controls impulse-dependent dopamine release induced by amphetamine in the nucleus accumbens. J Neurochem 89: 494-502.
50. Westerink BHC, Enrico P, Feimann J, De Vries JB (1998). The pharmacology of mesocortical dopamine neurons. A dual-probe microdialysis study in the ventral tegmental area and prefrontal cortex of the rat brain. J Pharmacol Exp Ther 285:143-154.
51. Willems PJ, Reyniers E, Oostra BA (1995). An animal model for fragile X syndrome. Ment Retard Dev Dis Res Rev 1:298-302.
52. Zahrt J, Taylor JR, Mathew RG, Arnsten AF (1997). Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17:8528-8535.
53. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R (2001). Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98:1982-1987.